SASTASUNDARVENTURES Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹341 Cr
verification pending
Revenue YoY
22%
reported change
EBITDA
Pending
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sastasundar Ventures delivered a strong Q3 FY26 with revenue of ₹341 crore (+22% YoY) and a sharp operating turnaround to EBIT positive ₹1 crore from a loss of ₹37 crore in Q3 FY25. The company cited resumed growth momentum after automation-related disruptions in prior quarters, with B2B (Retailer Shaki) and B2C (Sastasundar) both showing traction. Gross margins expanded 160bps YoY to 7.6% driven by improved product mix. Management reaffirmed its capital-efficient model with only ₹83 crore deployed in IP-driven businesses, and targets EBITDA breakeven for Retail by Q4 FY26 and contribution margin breakeven for B2C in FY27. The JTO generic brand launched leveraging the existing 65,000 retailer network, targeting 2-3% revenue contribution next year with 30% gross margins. Warehouse expansion (80,000 sq ft in West Bengal, 1 lakh sq ft in Noida) and AI investments (₹25 crore annual budget) underpin the growth roadmap. Key risks include GST working capital drag, slower-than-expected B2C scaling, and potential channel conflict with pharma companies on the JTO brand.
Colored figures show movement against the previous available record.
Guidance to track
- The B2B retail distribution platform is expected to turn EBITDA positive in the current quarter (Q4 FY26), supported by automation benefits and volume growth recovering to prior trajectory.
- The Sastasundar B2C platform is on track for contribution margin positivity in FY27, with January already showing positive contribution at the monthly level.
- The JTO generic brand distribution through 65,000 pharmacy retailers is expected to reach 2-3% of total revenue in FY27 and 10% within 3-4 years, with 30% gross margins.
- Management internally targets 30%+ compound annual growth rate for the next 5-10 years, subject to quarterly volatility from automation and expansion cycles.
Risks flagged
- The B2C segment (Sastasundar) posted ₹44 crore quarterly revenue, recovering from ₹35 crore earlier. Management targets 100% growth next year to reach levels previously handed to Flipkart, but execution on customer acquisition and repeat orders remains uncertain given heavy technology investment phase.
- The GST rate reduction from 12% to 5% on medicines left the company with accumulated input tax credit on inventory. Management acknowledged ₹2-3 years of working capital pressure while awaiting adjustment through higher-GST product sales. One month extra credit from pharma companies has already been utilized.
- An analyst directly questioned how the business model remains defensible given everything is in public domain. Management cited 10-year relationship building with pharma companies and ₹2,000 crore equivalent cost to replicate distribution rights, plus 5 years to build technology and warehouse efficiency. However, no patent protection exists for the core model.
- An analyst raised concerns about conflict between the JTO generic brand and pharmaceutical companies supplying branded medicines through the platform. Management argued the customer segments are different (price-sensitive vs branded), but the risk of strained pharma relationships remains unaddressed.
Key quotes
- We have not delayed a single day payment to any pharmaceutical companies. Our track record is absolutely 100% tight. We have not had any dispute of any single paisa with any pharmaceutical company.
- The company like retailer shaki we have not spent a single penny of acquiring any rights. Whatever money we are spending in building our technology and building our brand, that is paying off to us and will continue to pay in future.
- This is a business where only 83 crore rupees we have invested in building the entire IP business including retailer shaki and sastasundar. You can compare any other digital company in India which can demonstrate this kind of capital efficiency and working capital efficiency. I will be happy to learn.
Research modules